4D Molecular Therapeutics Inc. (FDMT): Price and Financial Metrics

4D Molecular Therapeutics Inc. (FDMT): $7.64

0.20 (+2.69%)

POWR Rating

Component Grades













Add FDMT to Watchlist
Sign Up

Industry: Biotech



in industry


  • FDMT scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.55% of US stocks.
  • The strongest trend for FDMT is in Growth, which has been heading down over the past 179 days.
  • FDMT's current lowest rank is in the Quality metric (where it is better than 9.74% of US stocks).

FDMT Stock Summary

  • 4D Molecular Therapeutics Inc's stock had its IPO on December 11, 2020, making it an older stock than merely 1.54% of US equities in our set.
  • FDMT's price/sales ratio is 29.22; that's higher than the P/S ratio of 94.53% of US stocks.
  • FDMT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 7.91% of US stocks.
  • If you're looking for stocks that are quantitatively similar to 4D Molecular Therapeutics Inc, a group of peers worth examining would be SLDB, RARE, ONCT, RGNX, and SRRK.
  • To check out 4D Molecular Therapeutics Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001650648.

FDMT Valuation Summary

  • In comparison to the median Healthcare stock, FDMT's price/earnings ratio is 139.73% lower, now standing at -14.5.
  • FDMT's EV/EBIT ratio has moved up 7.6 over the prior 38 weeks.
  • FDMT's price/sales ratio has moved down 77.6 over the prior 38 weeks.

Below are key valuation metrics over time for FDMT.

Stock Date P/S P/B P/E EV/EBIT
FDMT 2021-08-31 60.6 3.4 -14.5 -10.2
FDMT 2021-08-30 60.2 3.4 -14.4 -10.1
FDMT 2021-08-27 63.0 3.6 -15.1 -10.8
FDMT 2021-08-26 61.9 3.5 -14.9 -10.6
FDMT 2021-08-25 61.7 3.5 -14.8 -10.5
FDMT 2021-08-24 59.7 3.4 -14.3 -10.0

FDMT Price Target

For more insight on analysts targets of FDMT, see our FDMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.00 Average Broker Recommendation 1.5 (Moderate Buy)

FDMT Stock Price Chart Interactive Chart >

Price chart for FDMT

FDMT Price/Volume Stats

Current price $7.64 52-week high $36.14
Prev. close $7.44 52-week low $6.92
Day low $6.99 Volume 188,300
Day high $7.74 Avg. volume 213,193
50-day MA $12.14 Dividend yield N/A
200-day MA $20.35 Market Cap 246.77M

4D Molecular Therapeutics Inc. (FDMT) Company Bio

4D Molecular Therapeutics is a biotechnology company. The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

FDMT Latest News Stream

Event/Time News Detail
Loading, please wait...

FDMT Latest Social Stream

Loading social stream, please wait...

View Full FDMT Social Stream

Latest FDMT News From Around the Web

Below are the latest news stories about 4D Molecular Therapeutics Inc that investors may wish to consider to help them evaluate FDMT as an investment opportunity.

4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors

EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies announced that Professor David Schaffer, Ph.D. has resigned as a director of 4D Molecular Therapeutics. Professor Schaffer’s transition coincides with the evolution of 4DMT into a clinical-stage gene therapy company with five products in clinical development and plans to develop pre-commercial

Yahoo | February 22, 2022

4D Molecular Therapeutics (FDMT) WORLDSymposium 2022 - 4D-310 Updated Interim Clinical Data - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th . Details of the fireside chat are as follows:

GlobeNewswire | February 11, 2022

4D Molecular Shares Updated Data From Fabry Disease Trial

4D Molecular Therapeutics Inc (NASDAQ: FDMT ) has … Full story available on Benzinga.com

Benzinga | February 9, 2022

4D Molecular Therapeutics reports phase 1/2 trial interim data of 4D-310 in Fabry disease

4D Molecular Therapeutics (FDMT) reported updated interim data from the ongoing phase 1/2 trial of 4D-310 in patients with Fabry disease.Following 4D-310 infusion, mean serum AGA

Seeking Alpha | February 9, 2022

Read More 'FDMT' Stories Here

FDMT Price Returns

1-mo -37.68%
3-mo -46.54%
6-mo -64.33%
1-year -71.23%
3-year N/A
5-year N/A
YTD -65.18%
2021 -47.07%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4511 seconds.